Earnings Call Summary | Spero Therapeutics(SPRO.US) Q4 2023 Earnings Conference
Earnings Call Summary | Spero Therapeutics(SPRO.US) Q4 2023 Earnings Conference
The following is a summary of the Spero Therapeutics, Inc. (SPRO) Q4 2023 Earnings Call Transcript:
以下是Spero Therapeutics, Inc.（SPRO）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Spero Therapeutics reported having cash and cash equivalents worth $76.3 million as of December 31, 2023.
Spero received a total of $95 million in milestones from GSK, to be paid in installments during 2024 and 2025.
Total revenue for Q4 2023 was $73.5 million, up from $47.4 million in Q4 2022. Total revenue for 2023 was $103.8 million, nearly double the $53.5 million revenue in 2022, mostly due to collaborations with GSK and Pfizer.
R&D expenses for 2023 totaled $51.4 million, slightly up from $47.6 million in 2022. G&A expenses were reduced to $25.6 million from $36.5 million in the previous year.
The net income reported for Q4 2023 was $51.2 million, with a full-year net income of $22.8 million; this was reflected in diluted earnings per share of $0.96 and $0.43 respectively.
Spero Therapeutics報告稱，截至2023年12月31日，現金及現金等價物價值7,630萬美元。
Spero從葛蘭素史克獲得了總額爲9500萬美元的里程碑資金，將在2024年和2025年分期支付。
2023年第四季度的總收入爲7,350萬美元，高於2022年第四季度的4,740萬美元。2023年的總收入爲1.038億美元，幾乎是2022年的5,350萬美元收入的兩倍，這主要歸因於與葛蘭素史克和輝瑞的合作。
2023年的研發費用總額爲5140萬美元，略高於2022年的4,760萬美元。併購費用從去年的3,650萬美元減少到2560萬美元。
2023年第四季度報告的淨收益爲5,120萬美元，全年淨收入爲2,280萬美元；這反映在攤薄後的每股收益分別爲0.96美元和0.43美元。
Business Progress:
業務進展：
SPR720 designed for NTMPD progressed to a Phase 2a proof-of-concept clinical trial, with data due by the second half of the year. Two Phase 1 studies involving the intrapulmonary pharmacokinetics of SPR719 are also underway.
Phase 3 trials of tebipenem HBr for treating urinary tract infections have started in January, with a target enrollment of 2,648 patients, to be completed by 2025.
FDA clearance received for SPR206, an antibiotic for multi-drug resistant gram-negative infections.
SPR720 has also received several recognitions including orphan drug, QIDP, and Fast Track designations.
Partnerships with GSK, Pfizer, and Everest, and associations with government agencies, have secured funding for business operations.
A strong balance sheet and financial flexibility position Spero to execute its plans effectively.
專爲 NTMPD 設計的 SPR720 已進入 2a 期概念驗證臨床試驗，數據將於下半年公佈。兩項涉及 SPR719 肺內藥代動力學的 1 期研究也在進行中。
用於治療尿路感染的替比培南HBr的3期試驗已於1月開始，目標招收2648名患者，到2025年完成。
用於耐多藥革蘭陰性感染的抗生素 SPR206 已獲美國食品藥品管理局批准。
SPR720 還獲得了多項認可，包括孤兒藥、QIDP 和 Fast Track 稱號。
與葛蘭素史克、輝瑞和珠穆朗瑪峯的合作伙伴關係，以及與政府機構的協會，爲企業運營提供了資金。
強勁的資產負債表和財務靈活性使Spero能夠有效地執行其計劃。
More details: Spero Therapeutics IR
更多詳情： Spero 療法 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。